SEARCH RESULT

Total Matching Records found : 326

Conflict of interest in setting norms for pharmaceuticals in WHO -Rema Nagarajan

-The Times of India   NEW DELHI: The World Health Organisation's (WHO) work of setting up norms and standards for production of medicines seems to be flawed by a fundamental conflict of interest. At the heart of its standard setting work is an entity the International Conference on Harmonization (ICH) in which majority of the WHO member countries have no voting rights and which is dominated by pharmaceutical industry groups. This glaring...

More »

Onus on the state-Sagnik Dutta

-Frontline   A Delhi High Court verdict says the State government is bound to ensure that poor and vulnerable sections of society have access to treatment for rare and chronic diseases. SEVEN-YEAR-OLD Mohammed Ahmed Khan looked on helplessly as his father, Sirajuddin, narrated the sordid tale of the loss of four of his children to Gaucher's disease, a rare genetic disease that requires lifelong, exorbitantly expensive enzyme replacement therapy. Sirajuddin, a rickshaw...

More »

SC ruling on clinical trials

-The Telegraph   New Delhi: The Supreme Court today asked the Centre to allow clinical trials on new pharmaceutical compounds only after ensuring to the extent possible that their potential benefits outweigh their risks and they are needed in India. A bench of Justices R.M. Lodha and Kurien Joseph, responding to a public interest petition by a non-government organisation called Swasthya Adhikar Manch, also told the Centre to ensure that the candidate compounds...

More »

No country for whistle-blowers -Andrew M Beato and Narayan Lakshman

-The Hindu A strong whistle-blower protection law in India would expose financial corruption in a way that reinforces ethical business practices In 2013, generic pharmaceutical company Ranbaxy pleaded guilty to seven criminal felonies for drug manufacturing fraud and agreed to cough up an unprecedented $500 million in fines. The case against Ranbaxy was significant not only for being a successful prosecution of a powerful India corporation. It also marked the triumph of Dinesh...

More »

Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh

-Down to Earth Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close